|
|
|
| Clinical efficacy and cytology of pulsed high volume blood filtration in patients with septic shock |
| CAI Rong XU Hongming |
| Department of Emergency, Yuyao People′s Hospital of Zhejiang Province, Zhejiang Province, Yuyao 315400, China |
|
|
|
Abstract Objective To investigate the clinical effect and cytology of pulsed high volume blood filtration in septic shock patients. Methods From June 2015 to November 2016, 88 patients with septic shock in ICU of Yuyao People’s Hospital were selected. According to the different treatment methods, they were divided into control group and observation group, with 44 cases in each group. The control group was treated with continuous blood purification, and the observation group was treated with pulsed high-volume blood filtration 8-16. The levels of lactate, mean arterial pressure (MAP), acute physiology and chronic health evaluation(APACHEⅡ) score, C-reactive protein (CRP), interleukin 6 (IL-6), tumor necrosis factor (TNF-α), thrombomodulin (sTM), von Willebrand factor (vWF), endothelin-1 (ET-1), E-selectin (CD62E), soluble cell adhesion factor -1 (sICAM-1) before and after treatment for 3 days between two groups were compared. Results After 3 days of treatment, the levels of lactate, APACHEⅡ score, CRP, IL-6, TNF-α, sTM, vWF, ET-1, CD62E, sICAM-1 were lower than those before treatment (P < 0.01), the MAP higher than before treatment (P < 0.01). The levels of lactate, APACHEⅡ score, IL-6, TNF-α, vWF, ET-1, CD62E, sICAM-1 in the observation group were all lower than those of control group (P < 0.01), the MAP in the observation group was higher than control group (P < 0.01). Conclusion Pulsed high volume blood filtration has a positive clinical effect on patients with septic shock, which can improve the vital signs of patients and reduce the levels of TNF-α, IL-6, CRP, vWF, ET-1, CD62E and sICAM- 1 expression, suggesting that patients with vascular endothelial cells have a regulatory role.
|
|
|
|
|
|
[1] Bower G，Ashrafian H，Cappelletti S，et al. A proposed role for sepsis in the pathogenesis of myocardial calcification [J]. Acta Cardiol，2017，72（3）:1-7.
[2] 田金飞，汤彦.脓毒血症研究进展[J].内科急危重症志，2012，18（1）：14-16.
[3] 高戈，冯喆，常志刚，等.2012国际严重脓毒症及脓毒性休克诊疗指南[J].中华危重病急救医学，2013，25（8）：501-505.
[4] 洪峰，俞兴群，李远思，等.高容量血液滤过在脓毒性休克中的应用[J].安徽医学，2012，33（5）：526-528.
[5] Dellinger RP，Levy MM，Rhodes A，et al. Surviving sepsis campaign：international guidelines for management of severe sepsis and septic shock，2012 [J]. Intensive Care Med，2013，39（2）：165-228.
[6] Bosurgi R. International sepsis forum 2014 [J]. Lancet Infect Dis，2015，15（2）：155.
[7] 赵雪峰，魏秀华.脓毒血症患者血清IL-6以及IL-10的表达及对免疫功能的影响[J].中国实验诊断学，2017，21（2）：279-281.
[8] 王燕，刘静，曾宗跃，等.血presepsin对院内成人脓毒血症诊断价值的荟萃分析[J].临床检验杂志，2015，33（4）：316-319.
[9] 徐志伟，张洪.细胞因子转导抑制因子3对脓毒血症炎性因子及肺损伤的影响[J].实用医学杂志，2017，33（2）：218-221.
[10] 周荣，丁晓莉，刘良明，等.脂多糖致脓毒血症大鼠血管内皮细胞凋亡的实验观察[J].微循环学杂志，2015，（4）：7-10.
[11] Fung AWS，Beriault D，Diamandis EP，et al. The role of procalcitonin in diagnosis of sepsis and antibiotic stewardship：opportunities and challenges [J]. Clin Chem，63（9）：1436-1441.
[12] 黄阳，邢昌赢，储腊萍，等.间歇性高容量血液滤过对老年脓毒症合并多器官功能障碍综合征患者的疗效观察[J].中国医药导报，2011，8（13）：55-57.
[13] 陈伟明.早期应用不同剂量血液滤过治疗对脓毒症休克幼猪疗效及安全性研究[D].上海：复旦大学，2012.
[14] 赵春莉，董志扬，何洋，等.容量复苏联合连续静脉血滤治疗脓毒性休克的疗效观察[J].中华全科医师杂志，2015， 14（1）：47-50.
[15] 张莉.早期应用持续高容量血液滤过联合血液灌流对严重脓毒症治疗效果观察[J].中华临床医师杂志（电子版），2012，6（14）：3976-3980.
[16] 刘卫明，金同新，陆逢时，等.高容量连续性血液净化（CBP）治疗脓毒血症并急性肾损伤的临床疗效[J].辽宁医学杂志，2017，31（2）：9-11.
[17] 张文喜，段达荣，张震宇，等.参附注射液联合低分子肝素对小儿脓毒血症血浆NT-ProBNP、Cys、凝血功能和预后的影响[J].中国现代医学杂志，2017，27（2）：61-65.
[18] 章晋辉，赵群，邹圣强，等.降钙素原、C-反应蛋白、白细胞计数在脓毒症患者预后评估中的作用[J].中国医药导报，2016，13（13）：32-35.
[19] 李静，杨智，何周康，等.Presepsin与脓毒血症的研究进展[J].内科急危重症杂志，2016，22（2）：147-149.
[20] 王丹.复苏后补液对急性脓毒症休克的疗效[J].中国医药指南，2015，（1）：130-131. |
|
|
|
